SCHEMBL4072244

SCHEMBL4072244

Cc1cnccc1OC(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
BACE1 P56817 6/20 0.39
PDE2A O00408 2/20 0.38
PDE10A Q9Y233 2/20 0.38
PDE6D O43924 1/20 0.38
PDE6A P16499 1/20 0.38
PDE6G P18545 1/20 0.38
PDE6B P35913 1/20 0.38
PDE6C P51160 1/20 0.38
PDE6H Q13956 1/20 0.38
KDM4E B2RXH2 1/20 0.36
CA12 O43570 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
NOTUM Q6P988 1/20 0.33
CA1 P00915 1/20 0.33
TRPA1 O75762 1/20 0.33
PDE4A P27815 1/20 0.33
SIRT3 Q9NTG7 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4072595 0.82 NOTUM (0.37) CA12CA2CA9NOTUMCA1
SCHEMBL13724635 0.76 KDM4E (0.36) GAAKDM4ECA12CA2CA9
SCHEMBL4072241 0.76 KDM4E (0.36) GAABACE1KDM4ECA12CA2
SCHEMBL2644157 0.76 KDM4E (0.39) GAAKDM4ECA12CA2CA9
SCHEMBL2644153 0.76 KDM4E (0.36) GAABACE1PDE2APDE10APDE6D
SCHEMBL1106628 0.74
SCHEMBL31543981 0.73 KDM4E (0.37) GAAKDM4EPDE4AMAPTKMT2A
Hydrochloric Acid SCHEMBL28832304 0.73 CYP1A2 (0.36) PDE2APDE10ACA12CA2CA9
Hydrochloric Acid SCHEMBL29090737 0.72 CA12 (0.48) PDE2APDE10AKDM4ECA12CA2
SCHEMBL4076045 0.72 PDE10A (0.40) PDE2APDE10APDE6DPDE6APDE6G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572918-B2 Prepared in high yield and high purity without the need for isolation of intermediates and chromatographic purification; useful as muscarinic receptor antagonists; 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl)-hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine THERAVANCE, INC. (US) 2009-08-11 US disclosed
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2008-04-17 US disclosed
US-7285564-B2 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. (US) 2007-10-23 US disclosed
EP-1556372-B1 SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE INC (US) 2007-05-30 EP disclosed
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM4, CHRM3, CHRM1 GAA 3358/4885BACE1 2124/4885PDE2A 1038/4885
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM5, CHRM1, CHRM3 GAA 4256/4885BACE1 3184/4885PDE2A 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.